Menu Back toSession 5: De-Centralization of Clinical Trials – Different Stakeholder Perspectives

Clinical Trial Regulation Conference

Join experts from regulatory, ethics bodies, sponsors and patients to discuss the launch of the Clinical Trial Regulation and new trends of Clinical Trials in Europe.


Session 5: De-Centralization of Clinical Trials – Different Stakeholder Perspectives

Session Chair(s)

Elke  Stahl, PhD

Elke Stahl, PhD

  • CTFG Co-Chair, Clinical Trials expert
  • Federal Institute For Drugs and Medical Devices (BfArM), Germany
Getting insight in different stakeholders’ perspectives on decentralised clinical trials. Their experiences with decentralised elements gained in clinical (hybrid) trials - the advantages and challenges.

Speaker(s)

Mireille  Muller, DrSc, PhD, MSc

Sponsors Perspective

Mireille Muller, DrSc, PhD, MSc

  • Regulatory Policy & Intelligence Director
  • Novartis Pharma AG, Switzerland
Ghislaine  Van Thiel, PhD, MSc

Ethical Side of Digitalisation of Clinical Trials

Ghislaine Van Thiel, PhD, MSc

  • Ass. Professor Medical ethics
  • University Medical Center Utrecht, Netherlands
Greet  Musch, PhD

Regulators Perspective on Expectations for the Future?

Greet Musch, PhD

  • General Director
  • FAMHP, Belgium
Jan  Geissler, MBA

Patient Organisations – Advantages and Disadvantages of Digitalisation

Jan Geissler, MBA

  • Managing Director
  • Patvocates, Germany
Ruediger  Pankow, DrSc

Panel discussion with Q&A, with participation of:

Ruediger Pankow, DrSc

  • Principal Consultant, Regulatory Affairs
  • Parexel International, Germany

Contact us

Registration Questions?

Send Email
+41 61 225 51 51